1. Home
  2. SRAD vs VKTX Comparison

SRAD vs VKTX Comparison

Compare SRAD & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sportradar Group AG

SRAD

Sportradar Group AG

N/A

Current Price

$11.35

Market Cap

3.8B

Sector

Technology

ML Signal

N/A

Logo Viking Therapeutics Inc.

VKTX

Viking Therapeutics Inc.

N/A

Current Price

$24.95

Market Cap

3.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SRAD
VKTX
Founded
2001
2012
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.7B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
SRAD
VKTX
Price
$11.35
$24.95
Analyst Decision
Buy
Strong Buy
Analyst Count
23
21
Target Price
$17.38
★ $95.32
AVG Volume (30 Days)
2.3M
★ 3.8M
Earning Date
11-03-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.94
N/A
Revenue Next Year
$5.04
N/A
P/E Ratio
$49.48
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.39
$23.82
52 Week High
$24.17
$43.10

Technical Indicators

Market Signals
Indicator
SRAD
VKTX
Relative Strength Index (RSI) 37.21 40.45
Support Level N/A $23.82
Resistance Level $13.62 $36.01
Average True Range (ATR) 0.61 1.82
MACD -0.22 -0.10
Stochastic Oscillator 0.13 0.56

Price Performance

Historical Comparison
SRAD
VKTX

About SRAD Sportradar Group AG

Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Share on Social Networks: